Eralfon 40000 IU 1 ml syringe with needle protection device

Active ingredient

Epoetin alfa

Composition

1 syringe contains 40000 IU of recombinant human erythropoietin

Excipients:

Sodium chloride – 5.84 mg,

sodium citrate pentasquihydrate – 5.8 mg or sodium citrate dihydrate – 4.776 mg,

albumin solution (in terms of dry albumin) – 2.5 mg,

citric acid monohydrate – 0.057 mg,

d/i water – up to 1 ml.

How to take, the dosage

Administered by injection by injection or intravenously. When changing the method of administration the drug is administered in the same dose, then the dose is adjusted if necessary (to achieve the same therapeutic effect when administered p/v the dose is 20-30% lower than when administered intravenously).

Interaction

Decreases cyclosporine concentration due to increased binding to red blood cells (cyclosporine dose adjustment may be necessary).

Special Instructions

During treatment, BP should be monitored weekly and general blood counts (including platelets, hematocrit, and ferritin) should be performed. In pre- and postoperative period Hb should be monitored more frequently if baseline was less than 140 g/l.

Contraindications

Absolute contraindications have not been identified.

Side effects

In the beginning of treatment there may be flu-like symptoms: dizziness, somnolence, feverishness, headache, myalgia, arthralgia.

Systems: dose-dependent increase of BP, worsening of arterial hypertension course (most frequently in patients with chronic renal failure); in single cases – hypertensive crisis, sharp increase of BP with encephalopathy symptoms (headache, mental confusion) and generalized tonic-clonic convulsions.

Hematopoietic organs: thrombocytosis, in some cases – thrombosis of shunt or arteriovenous fistula (including patients on hemodialysis with a tendency to arterial hypotension or with aneurysm, stenosis), aplasia of red blood cell generation.

Allergic reactions: skin rash (mild to moderately expressed), eczema, urticaria, pruritus, angioedema.

Local reactions: hyperemia, burning, mild to moderate soreness at the injection site (more common with pneumonic administration).

Laboratory findings: decreased serum ferritin concentration, in uremia – hyperkalemia, hyperphosphatemia.

Others: complications associated with respiratory distress or with a decrease in BP, immune reactions (induction of antibody formation), exacerbation of porphyria.

Overdose

Symptoms: intensification of side effects.

Similarities

Binocrit